

Article

# Exploring the Formation of Polymers with Anti-Amyloid Properties within the 2',3'-Dihydroxyflavone Autoxidation Process

Andrius Sakalauskas , Agne Janoniene, Gediminas Zvinys, Kamile Mikalauskaite, Mantas Ziaunys and Vytautas Smirnovas \* 

Institute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania

\* Correspondence: vytautas.smirnovas@bti.vu.lt

**Abstract:** Amyloid- $\beta$  and  $\alpha$ -synuclein aggregation into amyloid fibrils is linked to the onset and progression of Alzheimer's and Parkinson's diseases. While there are only a few disease-modifying drugs, it is essential to search for new, more effective ways to encounter these neurodegenerative diseases. Multiple research articles have shown that the autoxidation of flavone is a critical factor for activating the inhibitory potential against the protein aggregation. Despite this, the structure of the newly-formed inhibitors is unknown. In this research, we examined the autoxidation products of 2',3'-dihydroxyflavone that were previously shown to possess one of the most prominent inhibitory effects against amyloid- $\beta$  aggregation. Their analysis using HPLC suggested the formation of polymeric molecules that were isolated using a 3 kDa cut-off. These polymeric structures were indicated as the most potent inhibitors based on protein aggregation kinetics and AFM studies. This revelation was confirmed using MALDI-TOF and NMR. We also show that active molecules have a tendency to reduce the Amyloid- $\beta$  and  $\alpha$ -synuclein aggregates toxicity to SH-SY5Y cells.

**Keywords:** aggregation; amyloid-beta; alpha-synuclein; flavone; inhibition; autoxidation; polymers



**Citation:** Sakalauskas, A.; Janoniene, A.; Zvinys, G.; Mikalauskaite, K.; Ziaunys, M.; Smirnovas, V. Exploring the Formation of Polymers with Anti-Amyloid Properties within the 2',3'-Dihydroxyflavone Autoxidation Process. *Antioxidants* **2022**, *11*, 1711. <https://doi.org/10.3390/antiox11091711>

Academic Editor: Justyna Godos

Received: 22 July 2022

Accepted: 27 August 2022

Published: 30 August 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Protein accumulation into insoluble aggregates is linked with neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1]. AD was recognized as the most prevalent neurological condition affecting over 50 million people worldwide [2] and is projected to increase to 76 million by 2030 [3]. The pathological hallmark of AD is the deposition of extracellular amyloid- $\beta$  (A $\beta$ ) peptide plaques and Tau neurofibrillary tangles in neuronal cells [4]. PD is known to be the second most common neurodegenerative disease after AD [5]. PD is considered a movement disorder caused by the accumulation of neuronal inclusions (Lewy Bodies) consisting of  $\alpha$ -synuclein (aSyn) aggregates [6,7]. While both disorders are associated with aggregation that causes the onset of the disease, it is essential and beneficial to search for a potential treatment that could affect the beginning and progression of AD and PD.

Many possible counters for these neurological disorders involve treatment using anti-amyloid drugs [8–11]. In order to be effective, these compounds should selectively bind to the aggregation-prone peptide or protein, stabilizing them or changing the aggregation pathway to form non-toxic amorphous aggregates [12]. With this knowledge, numerous different compound groups have been screened, sorting out only potential inhibitors. However, this number has been vastly reduced in the clinical trials leaving only a few that can be used in the symptomatic treatment against AD and PD [13,14]. Therefore, it is necessary to fully test and categorize the newly found inhibiting molecules and understand their practical sense as anti-amyloid compounds.

Flavones belong to a group of natural anti-oxidants that are found in nature in fruits, herbs, spices, and vegetables [15,16]. Besides their anti-microbial, anti-HIV, anti-cancer,

anti-platelet, neuroprotective, anti-mutagenic, anti-allergic and anti-inflammatory characteristics [17–19], they were also shown in multiple reports to possess anti-amyloid properties [20–22]. A large number of flavone derivatives are described as acetylcholinesterase (AChE) inhibitors which makes them appealing candidates for the symptomatic treatment of AD [23,24]. In fact, there are twice as many flavone AChE inhibitors than flavanones, meaning that the structural integrity of the C2-C3 bond is essential [25]. However, the stability of flavones is questionable. The derivatives possessing neighboring hydroxyl groups are very likely to autoxidize at neutral or basic pH, completely changing the nature of these molecules [21]. Nevertheless, autoxidation improves the inhibitory effect against A $\beta$  and insulin aggregation [20,22]. This effect is shown in studies covering different polyphenolic compound groups including flavones. The most famous is EGCG that possesses an inhibitory effect against aggregation of different proteins [26,27]. While the compound autoxidation mixture seems to have anti-amyloid features, it can hold components that have opposite or even cytotoxic effects. Therefore, it is essential to understand which autoxidation products exhibit inhibitory features towards protein aggregation.

The autoxidation of polyphenolic molecules can lead to multiple distinct products obtaining unique structures and features [28,29]. This process involves degradation, oxidative coupling [17,30,31], and polymerization [32]. A recent study shows that the browning of the epicatechin and epigallocatechin samples is related to the oxidative coupling where o-quinone intermediates participate [33]. A similar pattern is observed in the iron-mediated autoxidation of flavonoids that leads to the formation of dehydro-type dimers, while the autoxidative degradation results in the breakdown of the C ring and the formation of HBA, DHBA, THBA, and THPGA derivatives [34].

In order to identify the inhibitory molecules in the flavone oxidation mixture, we selected oxidized 2',3'-dihydroxyflavone, which has previously been shown to possess the highest inhibitory potential among number of tested flavones against A $\beta$  aggregation [21]. The 2',3'-dihydroxyflavone has a C2-C3 double bond catechol moiety and the absence of 3-hydroxyl group that should favor the stabilization of the o-quinone and the oxidation coupling [30]. In this work, we show that the 2',3'-dihydroxyflavone oxidation products range from small degradation to large oligomeric molecular compounds. The sample molecules were separated using a 3 kDa cut-off and examined using HPLC. The anti-aggregation effects were tested on A $\beta$  and aSyn aggregation. The fraction containing inhibitor molecules was scanned using MALDI-TOF and NMR.

## 2. Materials and Methods

**2',3'-dihydroxyflavone oxidation.** The 2',3'-dihydroxyflavone stock solution was prepared by dissolving 2',3'-dihydroxyflavone (Indofine Chemical Company, Inc., Hillsborough Township, NJ, USA) in dimethylsulfoxide (DMSO, Carl Roth) to a final concentration of 10 mM. The oxidation solution was prepared by diluting 10 mM stock solution with 10 mM sodium phosphate buffer (pH 8.0) and DMSO to yield a final flavone concentration of 0.5 mM in 9 mM sodium phosphate buffer solution containing 10% DMSO. The final 10% DMSO in buffer solution was used to increase the solubility. The autoxidation was carried out by incubating the solution in 37 °C for 100 h.

**Separation of oDHF fractions.** The oxidized 2',3'-dihydroxyflavone (oDHF) was distributed to the concentrators with a 3 kDa cut-off. The concentrators were spun at 4000 g for 20 min. The flowthrough consisting of <3 kDa molecular weight molecules (oDHF<sub>LOW</sub>) and a cut-off sample consisting of >3 kDa molecular weight molecules (oDHF<sub>HW</sub>) were separated. The oDHF<sub>HW</sub> fraction was washed using the 9 mM sodium phosphate buffer solution containing 10% DMSO (pH 8.0) (further referred to as oxidation buffer) to remove all low molecular weight compounds from the mixture. The oDHF<sub>HW</sub> was diluted to the original volume of oDHF to retain a comparable concentration of high molecular weight molecules in the sample (Figure S1 displays the sample preparation procedure).

**High-performance liquid chromatography.** The oDHF and its fractions (oDHF<sub>LOW</sub> and oDHF<sub>HW</sub>) were separated and analyzed using Shimadzu UFLC system with a CMB-

20A communication module, two LC20AD quaternary and isocratic pumps, a SIL-20AC autosampler, a CTO-20A column compartment and an SPD-M20A DAD detector (Shimadzu Corp., Kyoto, Japan). For the detection of the eluting molecules, the DAD spectra recording was set from 190 nm to 500 nm with a data rate of 12.5 Hz. The ODS-AQ HPLC separation column (15 × 4.6, 3 μm, YMC) was used together with a 1 cm guard column. The HPLC grade MeCN (Fisher Scientific) and Milli-Q water (18.2 MΩ cm<sup>-1</sup>, Milli-Q Plus system, Millipore Bedford, MA, USA) were used for the RP-HPLC separation.

The samples were separated using a ternary gradient consisting of ultrapure water (eluent A), MeCN (eluent B) and 1% TFA in ultrapure water (eluent C). A constant 10% flow of eluent C was used to maintain 0.1% TFA concentration in the column throughout the separation experiment. The gradient between eluents A and B was 18% (0 min), 81% (20 min), and 81% (28 min). Before each analytical run, the column equilibration (10 column volume) was performed. The column thermostat was set to 40 °C and the flow rate to 1 mL min<sup>-1</sup>.

**Solid state <sup>1</sup>H NMR spectroscopy.** <sup>1</sup>H solid-state NMR spectra were recorded on a Bruker spectrometer (400 MHz) (Billerica, MA, USA) in DMSO-D<sub>6</sub> using residual DMSO signals (2.50 ppm) as the internal standard, and proton chemical shifts were expressed in parts per million (ppm).

**MALDI-TOF mass analysis.** Full scan MALDI-TOF-MS mass spectra were performed on a Bruker Autoflex Speed (Billerica, MA, USA) using a 1 kHz smartbeam<sup>TM</sup>-II laser for MALDI. The mass spectra laser shots were collected for the spectra at a 19.5 kV acceleration voltage. The oDHF<sub>HW</sub> sample was prepared with 2,5-dihydroxybenzoic acid (2,5-DHB) and sinapinic acid (SA) matrixes.

Preparation of sample with 2,5-DHB matrix: 1 μL of 2,5-DHB solution (20 mg/mL in the 30% ACN [*v/v*] containing 0.1% TFA) and 1 μM of oDHF<sub>HW</sub> were deposited on the MALDI target plate and dried under vacuum.

Preparation of sample with SA matrix: saturated SA in EtOH was deposited on the MALDI target plate and dried under vacuum. Then 1 μL of SA solution (20 mg/mL in the 30% ACN [*v/v*] containing 0.1% TFA) and 1 μM of oDHF<sub>HW</sub> were deposited on the MALDI target plate and dried under vacuum.

**Purification of recombinant Aβ<sub>42</sub>.** The Aβ<sub>42</sub> peptide was expressed in *E. coli* BL-21Star<sup>TM</sup> (DE3) (Invitrogen, Carlsbad, CA, USA) and purified similarly as previously described [21]. In brief, the cell culture was grown for 15 h in a ZYM-5052 medium containing ampicillin (100 μg/mL). Then, after collecting the cell pellet, it was homogenized, sonicated, centrifuged and washed using 20 mM Tris/HCL and 1 mM EDTA buffer solution (pH 8.0). The procedure was repeated three times to remove all soluble proteins. Then, the remaining cell pellet was resuspended, homogenized and sonicated in the buffer solution containing 20 mM Tris/HCL, 8 M urea and 1 mM EDTA (pH 8.0). After centrifugation, the supernatant was diluted four times using 20 mM Tris/HCL, 1 mM EDTA buffer solution (pH 8.0) and mixed with 50 mL DEAE-Sepharose (equilibrated in the same buffer solution), and agitated using a magnetic stirrer at 80 rpm for 30 min at 4 °C. For the chromatography procedure, a Buchner funnel with Fisherbrand glass microfiber paper on a vacuum glass bottle was used. The resin was washed with the loading buffer (20 mM Tris/HCL, 1 mM EDTA pH 8.0), increasing NaCl concentration using a step gradient procedure. The steps contained 0, 20, 150, and 500 mM of NaCl in the loading buffer solution. The target protein was collected in the fraction containing 150 mM NaCl. Collected protein sample was flash-frozen, lyophilized and stored at -20 °C.

To separate any impurities from the target peptide, size exclusion chromatography (SEC) was performed. The lyophilized powder was dissolved in a 20 mM sodium phosphate buffer solution containing 5 M GuSCN (pH 8.0). The sample was then loaded on a Tricorn 10/300 column (packed with Superdex 75) and eluted at 1 mL/min using 20 mM sodium phosphate, 0.2 mM EDTA and 0.02% NaN<sub>3</sub> buffer solution (pH 8.0). The target peptide was eluted at around 15 min. The eluted protein fraction was lyophilized and stored at -20 °C. Before each experiment, the SEC procedure was repeated to prepare the fresh

peptide solution (without any oligomeric or fibrillar structures). The protein fraction with purified A $\beta$  was collected to the maximum recovery microtubes (Corning, New York, NY, USA) and stored on ice for 2 min, while the concentration was determined by integrating the UV absorbance peak ( $\epsilon_{280} = 1490 \text{ M}^{-1} \text{ cm}^{-1}$ ). Then, the peptide sample was diluted and immediately used for the experiments.

**Purification of recombinant aSyn.** aSyn was purified similarly as previously described [35]. In short, the cells with expressed aSyn were homogenized and then sonicated using a buffer solution containing 20 mM Tris/HCl, 0.5 M NaCl, 1 mM EDTA and 1 mM PMSF (pH 8.0). The supernatant was then heated for 20 min at 80 °C using a water bath. The aggregated proteins were centrifuged at 15,000  $\times g$  for 30 min at 4 °C, and then soluble aSyn (collected in the supernatant) was precipitated by adding ammonium sulphate (using ~40% saturation). The precipitated proteins were centrifuged and dissolved in a dialysis buffer solution containing 20 mM Tris/HCl, 1 mM EDTA, 0.5 mM DTT, and were dialyzed and loaded onto the HiScale 26/300 column (packed with DEAE-Sepharose equilibrated in the dialysis buffer). The target peptide was washed using a salt gradient (0.1 M NaCl). The collected fractions with aSyn were concentrated and loaded on HiLoad 26/600 column (packed with Superdex 75 pg) and eluted at 4 mL/min using a 50 mM ammonium bicarbonate buffer solution. The eluted protein was flash-frozen, lyophilized and stored at  $-20 \text{ }^{\circ}\text{C}$ .

**Aggregation kinetics of A $\beta$  peptide.** The purified peptide (1.5 mL, pH 8.0) was mixed with 3 mL 20 mM sodium phosphate buffer solution (pH 6.33) to yield a 3-fold diluted peptide solution (pH 7.0). The peptide was mixed with 20 mM sodium phosphate buffer (pH 7.0), 10 mM thioflavin-T (ThT) (Sigma-Aldrich, cat. No. T3516) stock solution, oxidation buffer and oDHF (or its fraction—oDHF<sub>LOW</sub>, oDHF<sub>HW</sub>) to the final reaction mixture, containing 1  $\mu\text{M}$  A $\beta$ , 20  $\mu\text{M}$  ThT, 10% (*v/v*) (percentages in all further cases are in form of *v/v*) of corresponding oDHF sample and 1% DMSO. For the experiments where a range of oDHF<sub>HW</sub> concentrations were used (0–20%), the initial oDHF<sub>HW</sub> was diluted using an oxidation buffer. The aggregation kinetics was followed in non-binding 96-well plates (Fisher, Waltham, MA, USA, cat. No. 10438082) (sample volume was 80  $\mu\text{L}$ ) at 37 °C by measuring ThT fluorescence using 440 nm excitation and 480 emission wavelengths in a ClarioStar Plus plate reader (BMG Labtech, Ortenberg, Germany).

**Aggregation kinetics of aSyn.** Lyophilized aSyn powder was dissolved in a 20 mM potassium phosphate buffer (pH 7.4) containing 300 mM NaCl and filtered through a 0.22  $\mu\text{m}$  syringe filter. The protein concentration was determined by measuring the sample absorbance at 280 nm using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) ( $\epsilon_{280} = 5960 \text{ M}^{-1} \text{ cm}^{-1}$ ). Then, the protein sample was mixed with 10 mM ThT stock solution, oxidation buffer and oDHF (or its fraction—oDHF<sub>LOW</sub>, oDHF<sub>HW</sub>) to a final reaction mixture, containing 100  $\mu\text{M}$  aSyn, 100  $\mu\text{M}$  ThT, 20% of corresponding oDHF sample and 2% DMSO. In case of aSyn fibril samples that were used with SH-SY5Y cells, the range of inhibitor concentration was used (0.1–40%). The kinetic experiments were performed similarly as mentioned above with A $\beta$  additionally using 600 RPM orbital agitation and each plate well containing a single 3 mm glass bead (sample volume was 100  $\mu\text{L}$ ).

**Atomic force microscopy (AFM).** Samples for AFM images were collected after kinetic measurements (experiment time-1000 min for A $\beta$  and 2500 min for aSyn) and scanned similarly as previously described [20]. In short, 40  $\mu\text{L}$  of 0.5% (*v/v*) APTES (Sigma-Aldrich, cat. No. 440140) in MilliQ water was deposited on freshly cleaved mica and incubated for 5 min. Then, the mica was carefully washed using 2 mL of MilliQ water and dried under gentle airflow and 40  $\mu\text{L}$  of each sample was deposited on the functionalized surface and incubated for another 5 min. Prepared samples were again washed using 2 mL of MilliQ water and dried under gentle airflow. AFM imaging was performed using a Dimension Icon (Bruker) atomic force microscope in tapping mode using RTESPA-300 probes. The 10  $\mu\text{m} \times 10 \mu\text{m}$  images of the 1024  $\times$  1024 pixel resolution were analyzed using Gwyddion 2.5.5 software. The heights and widths of the structures found on the mica were determined by tracing perpendicular to each structure axes.

**FTIR.** aSyn fibrils were pelleted by centrifuging at  $16,100\times g$  for 10 min. Then, the supernatant was removed, and 0.5 mL of D<sub>2</sub>O was added. This procedure was repeated three times to replace most of the water molecules with the D<sub>2</sub>O. After the last centrifugation step, the fibrils were resuspended in 80  $\mu$ L of D<sub>2</sub>O. The FTIR procedure was performed as previously described [36]. In brief, the spectra were recorded using an Invenio S IR spectrophotometer equipped with a Mercury Cadmium Telluride detector. The sample was placed in the CaF<sub>2</sub> transmission windows with 0.05 mm Teflon spacers, 256 interferograms of  $2\text{ cm}^{-1}$  resolution were averaged per spectrum. Before normalizing to the same area of Amide I region ( $1705\text{--}1595\text{ cm}^{-1}$ ), the D<sub>2</sub>O and water vapor spectrums were subtracted. The data were processed using GRAMS software (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

**Cell culturing.** SH-SY5Y human neuroblastoma cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, USA), supplemented with 10% Fetal Bovine Serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA), 1% Penicillin-Streptomycin (10,000 U/mL) (Gibco, Grand Island, NY, USA) at 37 °C in a humidified, 5% CO<sub>2</sub> atmosphere in a CO<sub>2</sub> incubator.

**MTT assay.** SH-SY5Y cells were seeded in a 96-well plate (15,000 cells/well) and were allowed to attach overnight. Then the medium was changed to the one containing A $\beta$  monomers or fibrils or aSyn fibrils with or without the different amounts of oDHF<sub>HW</sub> (2% to 20% of the three times concentrated sample) and different amounts of oDHF<sub>HW</sub> (2% to 20% of the three times concentrated sample) alone. The cell viability was not performed with aSyn monomers due to the aggregation conditions-constant agitation with glass beads which may disrupt the assay. To remove DMSO, the oDHF<sub>HW</sub> sample was lyophilized and resuspended in a 10 mM phosphate buffer (pH 8.0). Medium, containing buffers (20 mM phosphate buffer solution as A $\beta$  stock solution and 10 mM phosphate buffer as oDHF<sub>HW</sub> stock solution), served as a control. After 48 h of incubation 10  $\mu$ M of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (12.1 mM in PBS) was added to each well and left to incubate for 2 h. Then, 100  $\mu$ L of 10% SDS with 0.01 N HCl solution was added to each well to dissolve formazan crystals and, after 2 h, the absorbance at 570 nm and 690 nm (reference wavelength) of each well was measured using a ClarioStar Plus plate reader.


**LDH assay.** Quantification of LDH release into the medium was assessed using a cytotoxicity detection kit (Roche Applied Science, Germany) under the manufacturer's protocol. Briefly, SH-SY5Y cells were seeded in a 96-well plate (15,000 cells/well) and were allowed to attach overnight. Then the medium inside the wells was aspirated, and 100  $\mu$ L of Advanced DMEM (Gibco, Grand Island, NY, USA) was added to each well. Afterwards, A $\beta$  monomers with different oDHF<sub>HW</sub> concentrations were suspended in Advanced DMEM and were added to the wells (to reach 200  $\mu$ L total medium volume in each well), which resulted in the final 3  $\mu$ M A $\beta$  and range of oDHF<sub>HW</sub> (2–20%) concentrations. After 24 h of incubation, 100  $\mu$ L of the medium from each well was aspirated, centrifuged, and transferred into a TPP 96-well tissue culture test plate (Trasadingen, Switzerland). LDH reagent was added, and after 30 min of incubation at room temperature, the absorbance of wells was measured at 492 nm and 600 nm (reference wavelength) using a ClarioStar Plus plate reader.

**Data analysis.** The aggregation kinetics were followed at least in triplicate independent samples. The data analysis was performed by fitting the kinetic curves using Boltzmann's sigmoidal equation [36]. The relative halftime values were calculated based on the control sample in their specific microplate. The data were processed using Origin software (OriginLab, Northampton, MA, USA).

All the experiments with SH-SY5Y cells were performed at least in triplicate independent measurements. The obtained values are represented as mean with standard deviation. Student's t-test was used to evaluate statistical significance between the groups with a probability of \*  $p < 0.05$ , \*\*  $p < 0.01$ , and \*\*\*  $p < 0.001$ .

### 3. Results

It is known that the autoxidation of polyphenolic compounds may lead to the formation of the higher mass molecules as a result of oxidation and interflavic coupling reactions [31]. Due to this, we first separated coupling and degradation products of the oxidized 2',3'-dihydroxyflavone (oDHF) mixture using a concentrator (3 kDa cut-off). The 2',3'-dihydroxyflavone, oDHF and its fractions of lower molecular weight (oDHF<sub>LOW</sub>) and higher molecular weight (oDHF<sub>HW</sub>) components were analyzed using HPLC separation (Figure 1A). The 2',3'-dihydroxyflavone autoxidized to many different components seen in the chromatogram. The shallow and broad peak (12–27 min) resembles the elution of the mixture containing various lengths of oligomeric molecules [37]. Most of the eluting peaks in the oDHF<sub>LOW</sub> sample separation were within the 2.5–17.5 min range. In the case of oDHF<sub>HW</sub>, the chromatogram mainly contains a shallow peak that is typical for a broad range of oligomeric species (12–27 min). Except for this, the chromatogram contains a few peaks that are also visible in the oDHF<sub>LOW</sub> chromatogram.



**Figure 1.** Chromatographic separation of 2',3'-dihydroxyflavone, oDHF and oDHF fractions (oDHF<sub>LOW</sub> and oDHF<sub>HW</sub>) (A). aSyn (100 μM) (B,D,F) and Aβ (1 μM) (C,E,G) aggregation kinetics in the presence of oDHF, oDHF<sub>LOW</sub> and oDHF<sub>HW</sub> (20% for aSyn and 10% for Aβ experiments) and their respective relative half-time values (H,I). The relative half-time values were calculated based on the control sample and error bars are one standard deviation (n = 3).


To further test the inhibitory effect of each sample, the oDHF, oDHF<sub>LOW</sub> and oDHF<sub>HW</sub> were used in the aSyn (Figure 1B,D,F) aggregation experiment. When using oDHF, the aggregation is stochastic ( $t_{50}$  values are highly dispersed) and reaches plateau at twice as low ThT intensity values compared to the control sample. Similar diminished ThT intensity values were seen in the experiments with oDHF<sub>HW</sub>, where the relative half-time was the highest amongst the tested inhibitor samples. However, the oDHF<sub>LOW</sub> had the lowest effect on aSyn aggregation, only slowing down the aggregation by ~25%. A similar result is seen in the aggregation experiments with Aβ (Figure 1C,E,G). The oDHF and oDHF<sub>HW</sub>

greatly diminished the ThT intensity, while oDHF<sub>LOW</sub> had no effect. This effect of ThT quenching, which has no impact on or correlation with the number of aggregates formed, was previously assessed in the literature [21]. The relative half-time values (Figure 1H,I) followed the same trend, where the oDHF<sub>HW</sub> showed a significantly higher inhibitory effect than the oDHF. At the same time, the oDHF<sub>LOW</sub> did not possess any influence on the aggregation time of A $\beta$ .

Based on the results presented in Figure 1, we have further investigated the oDHF<sub>HW</sub> sample. First, we measured the mass spectrum with MALDI-TOF using positive ionization and two ionization matrices (Sinapinic acid and 2,5-DHB) (Figure S2). The results revealed a number of different  $m/z$  values ranging from 400  $m/z$  to 2000  $m/z$ . The  $m/z$  difference between maxima of adjacent peak clusters was measured to be constant ( $\sim 246.51 \pm 0.36$  molar mass (the  $Z$  value was determined to be equal to one)). The visible pattern of  $m/z$  distribution is specific to the polymeric structure. It may be that lower molecular weight compounds did oversaturate the detector, limiting the observation of higher molecular weight polymers. It is worth noting that the lowest  $m/z$  values did not match the mass of 2',3'-dihydroxyflavone (254,238), nor the mass difference between different lengths of polymers. In addition, the 2',3'-dihydroxyflavone and oDHF<sub>HW</sub> NMR spectra display different characteristics (Figure S3). The unoxidized flavone NMR spectrum exhibits intense and narrow peak signals assigned to the initial flavone structure. The opposite spectrum is seen in the case of the oDHF<sub>HW</sub> sample. A broad multiplet in the aromatic region is observed (between 6.33 and 8.68 ppm), which indicates a formation of potentially branched polydisperse polymers. The high level of polydispersity of oDHF<sub>HW</sub> was confirmed using DLS measurement data (data not shown). Such findings correlate with eight aromatic protons (atoms 1–3, 6, 9, 13–15) observed in 2',3'-dihydroxyflavone NMR spectra (Figure S2B,C). Protons of hydroxyl groups (18 and 19, 10.00 and 9.57 ppm respectively) were not present in the proton NMR spectra of oDHF<sub>HW</sub>.

To characterize the inhibitory effect of oDHF<sub>HW</sub> against A $\beta$  aggregation, a range of inhibitor concentrations was used (Figure 2A). The ThT fluorescence intensity was diminished with the increasing concentration of oDHF<sub>HW</sub>. The ThT fluorescence intensity was lowered by half using 1% of oDHF<sub>HW</sub> and was entirely reduced to the noise level when the oDHF<sub>HW</sub> concentration was 20% (Figures 2A and S4). However, the A $\beta$  aggregation relative half-time relationship with the oDHF<sub>HW</sub> concentration (Figure 2D) followed two different trends that had a point of discontinuity at 2% of oDHF<sub>HW</sub> concentration. The lower concentrations slightly decrease (up to 10%) the aggregation half-time, enhancing the fibrillization rate. The inhibitory effect, which seems to have affected both nucleation and elongation stages, occurred only when using a 4% or higher inhibitor concentration. The 20% oDHF<sub>HW</sub> relative aggregation half-time value was excluded from the graph because of the low ThT fluorescence intensity that would result in low-quality fit (Figure S4).


The SH-SY5Y cell viability (Figure 2B) and LDH release (Figure 2E) tests were performed to understand whether the inhibition of A $\beta$  aggregation also reduces its cytotoxicity to cells. The oDHF<sub>HW</sub> alone did not significantly affect the cell viability and LDH release at any used concentration. Despite that, when A $\beta$  monomers and oDHF<sub>HW</sub> were incubated with cells, the survivability adopted the non-linear correlation. When the oDHF<sub>HW</sub> concentration was 2%, the cell survivability and LDH release were the same as without the inhibitor. Increasing the concentration to 4% increased the cell viability to a statistically significant ( $p < 0.05$ ). Nonetheless, the higher oDHF<sub>HW</sub> concentration turned in the opposite direction, where the cell viability was lower than with A $\beta$  alone.



**Figure 2.** The kinetic curves of 1 μM Aβ aggregation with a range of oDHF<sub>HW</sub> (0%–20% *v/v*) (A), and their respective relative halftime values (D) compared to the control sample. SH-SY5Y cell viability (B) and LDH release (E) after incubating (48 and 24 h, respectively) with 3 μM of Aβ and different oDHF<sub>HW</sub> concentrations (% by *v/v*). SH-SY5Y cell viability after incubating 48 h with 3 μM Aβ (C) and 100 μM aSyn (F) fibrils formed with or without the oDHF<sub>HW</sub>. Student's *t*-test significance values were compared to the Aβ or aSyn controls, \* *p* < 0.05, \*\* *p* < 0.01, and \*\*\* *p* < 0.001. Relative aggregation halftime error bars are one standard deviation (*n* = 3) approximated using a linear fit.

The equal effect is seen when Aβ was aggregated with oDHF<sub>HW</sub>, and then the preformed fibrils were added to the SH-SY5Y cells medium and incubated for 48 h (Figure 2C). At the same time, there was no significant effect on the cell viability if the fibrils were formed without oDHF<sub>HW</sub> and only then mixed together and incubated (24 h at 37 °Celsius) before pooling them on cells. More favorable results were observed with the preformed fibrils of aSyn in the presence of a different concentration of oDHF<sub>HW</sub> (Figure 2F). When the oDHF<sub>HW</sub> concentration was 1% to 2%, a significant reduction (*p* < 0.001) of aSyn cytotoxic effect on SH-SY5Y cells was recorded. The higher concentration of inhibitors had less of an impact, although it significantly increased cell viability.

Atomic force microscopy imaging was employed to observe the structures formed during Aβ aggregation kinetics experiment in the presence of oDHF<sub>HW</sub> (concentration range 0–20%) (Figure 3A–E). The Aβ alone formed typical short 4–5 nm height fibrils that can be seen in the aggregation experiments using a low peptide concentration (1 μM) [38,39]. Very similar structures were observed with 1% of oDHF<sub>HW</sub>. However, the height (Figure 3G) and width (Figure 3H) distribution are more dispersed since oDHF<sub>HW</sub> (as a polymeric structure) (Figure 3F) was found on the mica in the form of round shape structures with height (4–15 nm) and width (20–40 nm) values larger than the Aβ alone. In the sample images where the oDHF<sub>HW</sub> concentration was higher (4% to 20%), the larger round shape structures were visible, potentially being the product of the Aβ and oDHF<sub>HW</sub> combination. These structures are statistically seen in the upward shift of maximum height and width mean and median values. No round shape structures, nor significant height or width distributions, were found in the samples of aSyn aggregates formed in the presence of oDHF, oDHF<sub>LW</sub> and oDHF<sub>HW</sub> (Figure S5A–F).



**Figure 3.** Atomic force microscopy (AFM) images of A $\beta$  without (A) and with 1% (B), 4% (C), 10% (D) and 20% (E) oDHF<sub>HW</sub> concentration and the 20% of oDHF<sub>HW</sub> alone (F). The height (G) and width (H) distribution of structures present on the mica, where box plots indicate mean  $\pm$  SD and error bars are in the 5–95% range (n = 50).

#### 4. Discussion

The interest in the autoxidation of polyphenolic molecules in protein aggregation studies is growing because it has been proven that the initial polyphenol does not have an effect against the aggregation process, while the autoxidation mixture possesses anti-amyloid features [20–22,26]. The 2′/3′-dihydroxyflavone autoxidation was confirmed in our study (Figure 1A), leading to the scarce amount of the initial compound and a variety of different end-products. These products were possibly formed during the processes of degradation, oxidation coupling and polymerization [30,33,34].

The initial strategy of using membrane concentrators was expected to aid in isolating the larger molecules fraction (considering the formation of polymeric structures) from the rest of the smaller molecules in the autoxidation sample. There is no real evidence about whether all oDHF<sub>HW</sub> molecules at the time of separation were more than 3 kDa molecular weight. In fact, the smaller molecules (<3 kDa) might not have passed through the membrane (3 kDa cut-off) because of the possible planar aromatic structure that cannot

bend through the multiple pores. Despite this fact, the separated fractions exhibited drastically different inhibition effects against protein aggregation (Figure 1B–I). The  $\text{oDHF}_{\text{HW}}$  had sustained all the inhibitory potential, while  $\text{oDHF}_{\text{LW}}$  only slightly impacted aSyn aggregation, providing the evidence that larger flavone autoxidation products can function as anti-aggregation agents. This may also reflect the idea that a different concentration of inhibitor is necessary for a significant inhibition of distinct protein/peptide aggregation processes. In particular, this inhibitor/protein ratio is significantly lower for aSyn compared to studies with  $\text{A}\beta$  [27]. For this reason, the lower amount of inhibitor that may be present in  $\text{DHF}_{\text{LW}}$ , is capable of slowing down the aggregation of aSyn, but not  $\text{A}\beta$ . In the case of  $\text{A}\beta$ , the molecular mass of the inhibitor must be larger than what passes through the 3 kDa membrane, while for aSyn, smaller polymeric molecules (that do pass through the membrane) also act as inhibitor compounds. This led to the assumption that only larger molecular mass components of the autoxidation sample possess the anti-amyloid features.

The larger mass molecules from the DHF autoxidation sample adopted polydisperse polymeric characteristics, loss of the hydroxyl groups and coordination with sodium ions (the mass of neighboring peaks differ by 23 Da (Figures S2 and S3)). These findings indicate that the autoxidation of 2',3'-dihydroxyflavone (pH 8.0) leads to the polymerization of intermediate products. The literature describes a potential pathway through the formation of quinone moiety in the B ring [30,33]. Such motifs are more likely to form when flavones possess the C2-C3 double bond and absence of 3-OH group. Flavones that contain the aforementioned characteristics and neighboring hydroxyl groups are also shown to oxidize and exhibit anti-amyloid features [21]. However, the MALDI-TOF results suggest that the polymerization mechanism is more complex. The measured monomeric mass difference (246–247 Da) leads to an assumption that the polymerization occurs after further molecular changes or coupling of degradation products.

Since the inhibitor is a polymer, it is necessary to discuss its impact on protein aggregation. The AFM data in this work suggest the formation of higher and wider round-shaped structures. These macromolecules might be the reaction products between the inhibitor and a certain form of  $\text{A}\beta$  structure (monomer/oligomer or fibrillar) (Figure 3). The increasing concentration of  $\text{oDHF}_{\text{HW}}$  reduces the aggregation rate; however, this trend does contradict the cell viability assay. This inconsistency between results may be related to ThT fluorescence quenching by the inhibitor molecules, which reduces the signal intensity but not the formation of fibrillar structures. The longer aggregation term may lead to the formation of different  $\text{A}\beta$  aggregation intermediate products through a changed aggregation pathway that resulted in different cytotoxic effects on the SH-SY5Y cells (Figure 2B,E). In fact, the preformed fibrils with  $\text{oDHF}_{\text{HW}}$  showed similar cell viability results, meaning that the cytotoxic effect is exhibited by the end products. At the same time, the cytotoxicity tends to be gained during the initial protein aggregation phase as  $\text{oDHF}_{\text{HW}}$  did not change the  $\text{A}\beta$  cytotoxicity to cells when the fibrils were preformed without the inhibitor. On a positive note, the lower inhibitor concentrations reveal the reduced cytotoxicity of  $\text{A}\beta$  and aSyn. This outcome could probably be related to stabilization of protein monomeric/oligomeric species. Potentially, the 4% concentration of  $\text{oDHF}_{\text{HW}}$  in  $\text{A}\beta$  aggregation experiments leads to the formation of longer protofibrils that are covered with the inhibitor molecules, while at higher  $\text{oDHF}_{\text{HW}}$  concentrations, there are more inhibitor molecules that stabilize smaller oligomeric particles that are more toxic. Therefore, the margin of inhibitor concentration that diminishes the cytotoxic effect is narrow (at lower concentrations, there is no effect, while at higher there is decreased cell viability).

## 5. Conclusions

Taking all these results together, it appears that only part of the autoxidation products of 2',3'-dihydroxyflavone exhibit anti-amyloid effects against  $\text{A}\beta$  and aSyn. These molecules appear to be of a polymeric nature and bind to the oligomeric and fibrillar structures of  $\text{A}\beta$  increasing the cell viability; however, the effect is reversed at higher concentrations of inhibitor.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/antiox11091711/s1>, Figure S1: Oxidation of 2',3'-dihydroxyflavone and the separation procedure of the oxidation mixture; Figure S2: MALDI-TOF spectrum of oDHF<sub>HW</sub> prepared using SA (A) and 2,5-DHB (B) as a MALDI matrix material; Figure S3: The <sup>1</sup>H NMR spectra of oDHF<sub>HW</sub> and 2',3'-dihydroxyflavone recorded in DMSO-d<sub>6</sub> (A). Aromatic region (9.0–6.0 ppm) of oDHF<sub>HW</sub> (B) and the zoomed spectra (10.5–6.5 ppm) of 2',3'-dihydroxyflavone aromatic and hydroxyl groups region; Figure S4: The kinetic curves of 1 μM Aβ aggregation with 50 μM and 100 μM oDHF<sub>HW</sub>; Figure S5: Atomic force microscopy (AFM) images of aSyn without (A) and with oDHF (B), oDHF<sub>LW</sub> (C) and oDHF<sub>HW</sub> (D). The fibril height (E) and width (F) distribution, where box plots indicate mean ± SD and error bars are in the 5–95% range (n = 50). The FTIR spectra of aSyn fibrils formed with or without inhibitors (G) and their second derivatives (H).

**Author Contributions:** A.S. and V.S. designed the experiments, A.S., A.J., G.Z., M.Z. and K.M. performed the experiments, A.S., M.Z. and V.S. analyzed the data and prepared the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** European Social Fund under the Global Grant Measure, project number VP1-3.1-ŠMM-07-K-02-020 and Marie Curie Career Integration Grant 293476.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Chiti, F.; Dobson, C.M. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annu. Rev. Biochem.* **2017**, *86*, 27–68. [[CrossRef](#)] [[PubMed](#)]
2. Anand, A.; Patience, A.A.; Sharma, N.; Khurana, N. The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review. *Eur. J. Pharmacol.* **2017**, *815*, 364–375. [[CrossRef](#)] [[PubMed](#)]
3. World Health Organization. Dementia Fact Sheet. Available online: <https://www.who.int/news-room/fact-sheets/detail/dementia> (accessed on 10 June 2022).
4. Vaz, M.; Silvestre, S. Alzheimer's disease: Recent treatment strategies. *Eur. J. Pharmacol.* **2020**, *887*, 173554. [[CrossRef](#)] [[PubMed](#)]
5. Lebouvier, T.; Chaumette, T.; Paillusson, S.; Duyckaerts, C.; Bruley Des Varannes, S.; Neunlist, M.; Derkinderen, P. The second brain and Parkinson's disease. *Eur. J. Neurosci.* **2009**, *30*, 735–741. [[CrossRef](#)]
6. Ball, N.; Teo, W.P.; Chandra, S.; Chapman, J. Parkinson's disease and the environment. *Front. Neurol.* **2019**, *10*, 218. [[CrossRef](#)]
7. Söderbom, G. Status and future directions of clinical trials in Parkinson's disease. *Int. Rev. Neurobiol.* **2020**, *154*, 153–188. [[CrossRef](#)]
8. Athar, T.; Al Balushi, K.; Khan, S.A. Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. *Mol. Biol. Rep.* **2021**, *48*, 5629–5645. [[CrossRef](#)]
9. Peña-Bautista, C.; Casas-Fernández, E.; Vento, M.; Baquero, M.; Cháfer-Pericás, C. Stress and neurodegeneration. *Clin. Chim. Acta* **2020**, *503*, 163–168. [[CrossRef](#)]
10. Molino, S.; Dossena, M.; Buonocore, D.; Ferrari, F.; Venturini, L.; Ricevuti, G.; Verri, M. Polyphenols in dementia: From molecular basis to clinical trials. *Life Sci.* **2016**, *161*, 69–77. [[CrossRef](#)]
11. Ji, C.; Sigurdsson, E.M. Current Status of Clinical Trials on Tau Immunotherapies. *Drugs* **2021**, *81*, 1135–1152. [[CrossRef](#)]
12. Velander, P.; Wu, L.; Henderson, F.; Zhang, S.; Bevan, D.R.; Xu, B. Natural product-based amyloid inhibitors. *Biochem. Pharmacol.* **2017**, *139*, 40–55. [[CrossRef](#)] [[PubMed](#)]
13. Mullard, A. Controversial Alzheimer's drug approval could affect other diseases. *Nature* **2021**, *595*, 162–163. [[CrossRef](#)] [[PubMed](#)]
14. Srivastava, S.; Ahmad, R.; Khare, S.K. Alzheimer's disease and its treatment by different approaches: A review. *Eur. J. Med. Chem.* **2021**, *216*, 113320. [[CrossRef](#)] [[PubMed](#)]
15. Verma, A.K.; Pratap, R. The biological potential of flavones. *Nat. Prod. Rep.* **2010**, *27*, 1571–1593. [[CrossRef](#)] [[PubMed](#)]
16. Wang, X.; Cao, Y.; Chen, S.; Lin, J.; Bian, J.; Huang, D. Anti-Inflammation Activity of Flavones and Their Structure-Activity Relationship. *J. Agric. Food Chem.* **2021**, *69*, 7285–7302. [[CrossRef](#)]
17. Es-Safi, N.E.; Ghidouche, S.; Ducrot, P.H. Flavonoids: Hemisynthesis, reactivity, characterization and free radical scavenging activity. *Molecules* **2007**, *12*, 2228–2258. [[CrossRef](#)]
18. Singh, M.; Silakari, O. *Flavone: An Important Scaffold for Medicinal Chemistry*; Elsevier: Amsterdam, The Netherlands, 2018; ISBN 9780081020838.
19. Singh, M.; Kaur, M.; Silakari, O. Flavones: An important scaffold for medicinal chemistry. *Eur. J. Med. Chem.* **2014**, *84*, 206–239. [[CrossRef](#)]

20. Sato, M.; Murakami, K.; Uno, M.; Nakagawa, Y.; Katayama, S.; Akagi, K.I.; Masuda, Y.; Takegoshi, K.; Irie, K. Site-specific inhibitory mechanism for amyloid  $\beta$ 42 aggregation by catechol-type flavonoids targeting the lys residues. *J. Biol. Chem.* **2013**, *288*, 23212–23224. [[CrossRef](#)]
21. Sakalauskas, A.; Ziaunys, M.; Snieckute, R.; Smirnovas, V. Autoxidation Enhances Anti-Amyloid Potential of Flavone Derivatives. *Antioxidants* **2021**, *10*, 1428. [[CrossRef](#)]
22. Matos, A.M.; Cristóvão, J.S.; Yashunsky, D.V.; Nifantiev, N.E.; Viana, A.S.; Gomes, C.M.; Rauter, A.P. Synthesis and effects of flavonoid structure variation on amyloid- $\beta$  aggregation. *Pure Appl. Chem.* **2017**, *89*, 1305–1320. [[CrossRef](#)]
23. Khan, H.; Marya, Amin, S.; Kamal, M.A.; Patel, S. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. *Biomed. Pharmacother.* **2018**, *101*, 860–870. [[CrossRef](#)] [[PubMed](#)]
24. Yiannopoulou, K.G.; Papageorgiou, S.G. Current and Future Treatments in Alzheimer Disease: An Update. *J. Cent. Nerv. Syst. Dis.* **2020**, *12*, 1–12. [[CrossRef](#)]
25. Uriarte-Pueyo, I.; Calvo, I.M. Flavonoids as Acetylcholinesterase Inhibitors. *Curr. Med. Chem.* **2011**, *18*, 5289–5302. [[CrossRef](#)]
26. Sneideris, T.; Sakalauskas, A.; Sternke-Hoffmann, R.; Peduzzo, A.; Ziaunys, M.; Buell, A.K.; Smirnovas, V. The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG. *Biomolecules* **2019**, *9*, 855. [[CrossRef](#)] [[PubMed](#)]
27. Ziaunys, M.; Mikalauskaite, K.; Sakalauskas, A.; Smirnovas, V. Interplay between epigallocatechin-3-gallate and ionic strength during amyloid aggregation. *PeerJ* **2021**, *9*, e12381. [[CrossRef](#)] [[PubMed](#)]
28. Ramešová, Š.; Sokolová, R.; Tarábek, J.; Degano, I. The oxidation of luteolin, the natural flavonoid dye. *Electrochim. Acta* **2013**, *110*, 646–654. [[CrossRef](#)]
29. Sokolová, R.; Ramešová, Š.; Degano, I.; Hromadová, M.; Žabka, J. The oxidation of natural flavonoid quercetin. *Chem. Commun.* **2012**, *48*, 3433–3435. [[CrossRef](#)]
30. Bijlsma, J.; de Bruijn, W.J.C.; Velikov, K.P.; Vincken, J.P. Unravelling discolouration caused by iron-flavonoid interactions: Complexation, oxidation, and formation of networks. *Food Chem.* **2022**, *370*, 131292. [[CrossRef](#)]
31. Masuda, T.; Nojima, S.; Miura, Y.; Honda, S.; Masuda, A. An oxidative coupling product of luteolin with cysteine ester and its enhanced inhibitory activity for xanthine oxidase. *Bioorganic Med. Chem. Lett.* **2015**, *25*, 3117–3119. [[CrossRef](#)]
32. Di Gennaro, P.; Sabatini, V.; Fallarini, S.; Pagliarin, R.; Sello, G. Polyphenol Polymerization by an Alternative Oxidative Microbial Enzyme and Characterization of the Biological Activity of Oligomers. *Biomed. Res. Int.* **2018**, *2018*, 12–14. [[CrossRef](#)]
33. Tan, J.; De Bruijn, W.J.C.; Van Zadelhoff, A.; Lin, Z.; Vincken, J.P. Browning of Epicatechin (EC) and Epigallocatechin (EGC) by Auto-Oxidation. *J. Agric. Food Chem.* **2020**, *68*, 13879–13887. [[CrossRef](#)] [[PubMed](#)]
34. Chaaban, H.; Ioannou, I.; Paris, C.; Charbonnel, C.; Ghoul, M. The photostability of flavanones, flavonols and flavones and evolution of their antioxidant activity. *J. Photochem. Photobiol. A Chem.* **2017**, *336*, 131–139. [[CrossRef](#)]
35. Šneideris, T.; Baranauskienė, L.; Cannon, J.G.; Rutkienė, R.; Meškys, R.; Smirnovas, V. Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives. *PeerJ* **2015**, *2015*, 1–17. [[CrossRef](#)]
36. Ziaunys, M.; Sakalauskas, A.; Mikalauskaite, K.; Smirnovas, V. Polymorphism of Alpha-Synuclein Amyloid Fibrils Depends on Ionic Strength and Protein Concentration. *Int. J. Mol. Sci.* **2021**, *22*, 12382. [[CrossRef](#)] [[PubMed](#)]
37. Vonk, E.C.; Langeveld-Voss, B.M.W.; Van Dongen, J.L.J.; Janssen, R.A.J.; Claessens, H.A.; Cramers, C.A. Separation and characterization of oligomers by reversed-phase high-performance liquid chromatography; a study on well-defined oligothiophenes. *J. Chromatogr. A* **2001**, *911*, 13–26. [[CrossRef](#)] [[PubMed](#)]
38. Mastrangelo, I.A.; Ahmed, M.; Sato, T.; Liu, W.; Wang, C.; Hough, P.; Smith, S.O. High-resolution atomic force microscopy of soluble A $\beta$ 42 oligomers. *J. Mol. Biol.* **2006**, *358*, 106–119. [[CrossRef](#)] [[PubMed](#)]
39. Banerjee, S.; Sun, Z.; Hayden, E.Y.; Teplow, D.B.; Lyubchenko, Y.L. Nanoscale Dynamics of Amyloid  $\beta$ -42 Oligomers as Revealed by High-Speed Atomic Force Microscopy. *ACS Nano* **2017**, *11*, 12202–12209. [[CrossRef](#)]